- Home
- TECX vs AUTL Comparison
TECX vs AUTL Comparison
Compare TECX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- AUTL
- Stock Information
- Founded
- TECX 2019
- AUTL 2014
- Country
- TECX United States
- AUTL United Kingdom
- Employees
- TECX N/A
- AUTL N/A
- Industry
- TECX
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TECX
- AUTL Health Care
- Exchange
- TECX Nasdaq
- AUTL Nasdaq
- Market Cap
- TECX 334.4M
- AUTL 360.6M
- IPO Year
- TECX 2018
- AUTL 2018
- Fundamental
- Price
- TECX $19.76
- AUTL $1.32
- Analyst Decision
- TECX Buy
- AUTL Strong Buy
- Analyst Count
- TECX 6
- AUTL 5
- Target Price
- TECX $72.40
- AUTL $9.32
- AVG Volume (30 Days)
- TECX 203.0K
- AUTL 2.4M
- Earning Date
- TECX 05-08-2025
- AUTL 05-08-2025
- Dividend Yield
- TECX N/A
- AUTL N/A
- EPS Growth
- TECX N/A
- AUTL N/A
- EPS
- TECX N/A
- AUTL N/A
- Revenue
- TECX N/A
- AUTL $9,011,000.00
- Revenue This Year
- TECX N/A
- AUTL $277.74
- Revenue Next Year
- TECX N/A
- AUTL $221.89
- P/E Ratio
- TECX N/A
- AUTL N/A
- Revenue Growth
- TECX N/A
- AUTL N/A
- 52 Week Low
- TECX $1.40
- AUTL $1.11
- 52 Week High
- TECX $61.07
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TECX 49.14
- AUTL 45.63
- Support Level
- TECX $17.56
- AUTL $1.15
- Resistance Level
- TECX $21.99
- AUTL $1.44
- Average True Range (ATR)
- TECX 1.96
- AUTL 0.14
- MACD
- TECX 0.21
- AUTL 0.01
- Stochastic Oscillator
- TECX 46.15
- AUTL 29.82
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.